search
Back to results

Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (DESKTOPIII)

Primary Purpose

Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Tumor Debulking Surgery (surgery in recurrent ovarian disease)
Sponsored by
AGO Study Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Fallopian Tube Cancer focused on measuring Ovarian Cancer, Cancer of the fallopian tube, Primary peritoneal cancer, Recurrent disease, Platinum-sensitive, Surgery, Chemotherapy, Quality of Life, First recurrence of platinum sensitive:, Fallopian Tube Cancer, or Ovarian Cancer, or Peritoneal Cavity Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion criteria:

  • Patients with first recurrence of platinum sensitive, invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer of any initial stage.
  • Progression-free interval of at least 6 months after end of last platinum-containing therapy, or recurrence within 6 months or later after primary surgery if the patient has not received prior chemotherapy in patients with FIGO I. Non cytostatic maintenance therapy not containing platinum will not be considered for this calculation.

  • A positive AGO-score. Obligatory requirements for a positive AGO recurrence score in platinum-sensitive disease:

    1. Performance status ECOG 0
    2. No residual tumor after primary surgery (if unknown, alternatively primary FIGO stage I/II). If report from 1st surgery is not available contact study chairman who will decide whether inclusion is possible or not.
    3. Absence of ascites (cut off < 500 ml: radiological or ultrasound estimation)
  • Complete resection of the tumor by median laparotomy seems possible
  • Patients who have given their signed and written informed consent and their consent to data transmission and -processing.

Exclusion Criteria:

  • Patients with non-epithelial tumors as well as borderline tumors.
  • Patients without recurrence who are scheduled for diagnostic/second-look surgery or debulking surgery after completion of chemotherapy
  • More than one prior chemotherapy
  • Patients with second, third, or later recurrence
  • Patients with second malignancies who have been treated by laparotomy, as well as other neoplasms, if the treatment might interfere with the treatment of relapsed ovarian cancer or if major impact on prognosis is expected.
  • Patients with so-called platinum-refractory tumor, i.e. progression during chemotherapy or recurrence within 6 months after end of former first platinum-containing therapy
  • Only palliative surgery planned
  • Radiological signs suggesting metastases not accessible to surgical removal (i.e. complete resection is deemed impossible)
  • Any concomitant disease not allowing surgery and/or chemotherapy
  • Any medical history indicating excessive peri-operative risk
  • Any current medication inducing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents, bevacizumab)

Sites / Locations

  • Medizinische Universität Graz, Universitätsklinik für Frauenheilkunde Graz, Abteilung Gynäkologie u. Geburtshilfe
  • Universitätsklinikum Innsbruck, Univ. Klinik für Gynäkologie und Geburtshilfe
  • Medizinische Universität Wien,Universitätsklinik für Frauenheilkunde
  • Wilhelminenspital der Stadt Wien, Gynäkologisch und Geburtshilfliche Abteilung
  • UZ Leuven
  • Zhejiang Cancer Hospital, Gynecology Oncology
  • Fudan University Cancer Hospital, Gynecologic Oncology
  • Fudan University Zhongshan Hospital, Obstetrics and Gynecology
  • Suzhou Municipal Hospital, Gynecologic and Obstetrics
  • Aalborg Hospital
  • Aarhus University Hospital,Oncology
  • Ringshospitalet Copenhagen University Hospital; Oncology
  • Herlev Hospital
  • Odense University Hospital, Gynaecology and Obstetrics
  • Institut Bergonié, Gynecology
  • Centre Francois Baclesse
  • Centre Jean Perrin
  • Centre Antoine Lacassagne
  • Hôpital Européen Georges Pompidou
  • Hôpital Tenon
  • Insitut Jean Godinot, Service Rubis - Oncologie Médicale
  • Centre Eugène Marquis
  • Centre Hospitalier Universitaire Charles-Nicolle
  • Centre Henri Becquerel
  • Centre René Gauducheau
  • Centre Claudius Regaud
  • Hochtaunus-Kliniken gGmbH, Frauenklinik
  • Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde
  • Universitätsklinikum Carl Gustav Carus, Klinik für Frauenheilkunde u. Geburtshilfe
  • Evangelisches Krankenhaus, Frauenklinik
  • Kaiserswerther-Diakonie, Florence-Nightingale Krankenhaus, Gynäkologie
  • Kliniken Essen Mitte, Evang. Huyssens-Stiftung, Gynäkologische Onkologie
  • Klinikum der JWG Universität Frankfurt, Klinik für Gynäkologie und Geburtshilfe
  • Universitätsklinikum Freiburg, Frauenklinik
  • Klinikum Fürth, Frauenklinik Nathanstift
  • Gynecologic Clinic of the Ernst-Moritz-Arndt-University
  • Georg-August-Universität Göttingen, Universitäts-Frauenklinik
  • Medizinische Hochschule, Klinik für Frauenheilkunde u. Geburtshilfe
  • Klinikum Kempten, Klinik für Frauenheilkunde und Geburtshilfe
  • Universitätsklinikum Schleswig-Holstein Campus Kiel, Klinik f. Gynäkologie u. Geburtshilfe
  • Klinikum Konstanz, Frauenklinik
  • Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe
  • Universitätsklinikum Mainz, Frauenklinik
  • Klinikum Dritter Orden, Gynäkologie und Geburtshilfe
  • Klinikum der Universität München-Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
  • Oberschwaben Klinik, Krankenhaus St. Elisabeth, Frauenklinik
  • Caritas-Krankenhaus St. Josef, Klinik für Frauenheilkunde und Geburtshilfe d. Universität Regensburg
  • Leopoldina-Krankenhaus der Stadt Schweinfurt GmbH, Frauenklinik
  • Universitätsklinikum, Universitätsfrauenklinik
  • Ammerland-Klinik GmbH, Frauenklinik
  • HSK, Dr. Horst Schmidt Klinik GmbH, Klinik für Gynäkologie u. Gynäkologische Onkologie
  • Centro di Riferimento Oncologico,Struttura Operativa complessa Chirurgia Oncologica Ginecologica
  • Fondazione IRCCS Istituto Nazionale Tumori di Milano
  • Istituto Europeo di Oncologia, Divisione di Ginecologia
  • Istituto Nazionale Tumori di Napoli, Gynecologic Oncology
  • Seoul National University Hospital, Department of Obstetrics and Gynecology
  • Norwegian Radium Hospital, Oslo University Hospital, Gynecologic Oncology
  • ICO Badalona - H. U. Germans Trias i Pujol
  • Hospital de la Santa Creu i Sant Pau, Oncology
  • Hospital Clinic Barcelona, Oncology
  • ICO-Hospital Universitari de Girona Dr. Josep Trueta, Servicio de Oncologia de Girona
  • Avinguda Granvia de l'Hospitalet de Llobregat, Hospital de Bellvitge, Gynaecology
  • Hospital Son Llàtzer, Oncology
  • Hospital de Navarra, Oncology
  • Fundación Instituto Valenciano de Oncologia
  • Hospital Universitari i Politècnic la Fe, Oncology
  • Linköping University Hospital, Department of Obstetrics and Gynecology
  • Karolinska University Hospital, Oncology
  • Birmingham City Hospital, Cancer Research Team
  • Cambridge University Hospitals NHS FT - Addenbrookes Hospital, Gynaecological Oncology
  • Queen Elizabeth Hospital Gateshead, Northern gynaecological oncology centre
  • Royal Surrey Country Hospital,St Lukes Cancer Centre
  • Lincoln County Hospital, Oncology
  • St Bartholomew´s Hospital and Queen´s Hospital,Gynaecological Cancer Centre
  • University College London Hospital, Cancer clinical trails unit
  • Royal Marsden NHS Foundation Trust, Gynae research, Mulberry House
  • Imperial College Healthcare NHS Trust Hammersmith Hospital, Medical Oncology
  • Central Manchester Foundation NHS Trust, St Mary´s Hospital, Gynaecology
  • Queen Elizabeth the Queen Mother Hospital,East Kent Gynaeoncology Centre
  • Northampton General Hospital, Gynaecological Oncology
  • East and North Hertfordhire NHS Trust,Mount Vernon Hospital,Medical Oncology
  • Norfolk & Norwich University Hospital,Obstetrics & Gynaecology
  • Nottingham University Hospital, City Campus, Oncology
  • Royal Hallamshire Hospital & Weston Park Hospital, Cancer Clinical Trials Centre
  • Princess Anne Hospital, gynaecology
  • New Cross Hospital,Oncology/Gynaecology

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control Arm - Chemotherapy only

Procedure/Surgery

Arm Description

Chemotherapy for platinum-sensitive Ovarian Cancer can be selected on investigators choice

Maximum effort cytoreductive surgery

Outcomes

Primary Outcome Measures

Overall survival
in patients with platinum-sensitive recurrent ovarian cancer with a positive AGO Score

Secondary Outcome Measures

Progression free survival
patients with platinum-sensitive recurrent ovarian cancer with a positive AGO Score
Quality of Life measures with EORTC QLQ-C30 Global Health Status (GHS)
GHS scale-core item 29, 30; ranges 0-100
Quality of Life measures with EORTC QLQ-C30 Symptom Scale Insomnia
Item 11, ranges 0-100
Quality of Life measures with EORTC QLQ-C30 Symptom Scale Constipation
Item 16, ranges 0-100
Quality of Life measures with FACT-G total score
Composite of 27 items regarding physical, functional, social/family and emotional well-being. from 0-108
Quality of Life measures with FACT-O Ovarian Cancer subscale
Composite of 11 items regarding specific to Ovarian Cancer patients, ranges 0-44
Quality of Life measures with FACT-O total score
Sum of FACT-G and and Ovarian Cancer subscale, ranges 0-152

Full Information

First Posted
July 16, 2010
Last Updated
January 21, 2022
Sponsor
AGO Study Group
Collaborators
ARCAGY/ GINECO GROUP, Grupo Español de Investigación en Cáncer de Ovario, Cancer Research UK, Shanghai Gynecologic Oncology Group
search

1. Study Identification

Unique Protocol Identification Number
NCT01166737
Brief Title
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Acronym
DESKTOPIII
Official Title
A Randomized Multicenter Study to Compare the Efficacy of Additional Tumor Debulking Surgery vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
July 2010 (Actual)
Primary Completion Date
January 17, 2020 (Actual)
Study Completion Date
December 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AGO Study Group
Collaborators
ARCAGY/ GINECO GROUP, Grupo Español de Investigación en Cáncer de Ovario, Cancer Research UK, Shanghai Gynecologic Oncology Group

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
It is still not clear whether a positive AGO-score just selects patients with less aggressive biologic tumor behavior who as well would have had a positive outcome by chemotherapy only, or , if it is a score selecting patients who really benefit from surgery. Nevertheless, the AGO-score was confirmed to select patients with a less than 30% risk of ending with residual tumor after surgery for recurrent disease. This could avoid including patients into the present surgical protocol who could not benefit from an operationThe goal of this third DESKTOP study is to evaluate in a prospectively randomized multicentre setting, whether maximum effort of cytoreductive surgery followed by platinum based combination chemotherapy can improve overall survival as compared to platinum based combination chemotherapy alone in AGO-score positive patients.
Detailed Description
A predictive score identifying patients who might achieve a complete resection is deemed necessary to select the right patients for a prospective trial on cytoreductive surgery in relapsed ovarian cancer. Study centres are selected due to their surgical experience in ovarian cancer and/or participation in prior surgical trials in this field. Patients who matched eligibility criteria were allocated randomly 1:1 prospectively to cytoreductive surgery followed by platinum based combination chemotherapy or to platinum based combination chemotherapy alone .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Keywords
Ovarian Cancer, Cancer of the fallopian tube, Primary peritoneal cancer, Recurrent disease, Platinum-sensitive, Surgery, Chemotherapy, Quality of Life, First recurrence of platinum sensitive:, Fallopian Tube Cancer, or Ovarian Cancer, or Peritoneal Cavity Cancer

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
408 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Arm - Chemotherapy only
Arm Type
No Intervention
Arm Description
Chemotherapy for platinum-sensitive Ovarian Cancer can be selected on investigators choice
Arm Title
Procedure/Surgery
Arm Type
Experimental
Arm Description
Maximum effort cytoreductive surgery
Intervention Type
Procedure
Intervention Name(s)
Tumor Debulking Surgery (surgery in recurrent ovarian disease)
Intervention Description
Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
Primary Outcome Measure Information:
Title
Overall survival
Description
in patients with platinum-sensitive recurrent ovarian cancer with a positive AGO Score
Time Frame
Approximately 36 months after last patient randomized and observation of 244 events
Secondary Outcome Measure Information:
Title
Progression free survival
Description
patients with platinum-sensitive recurrent ovarian cancer with a positive AGO Score
Time Frame
Progression free survival is defined as interval between date of randomization and 2nd relapse/progression or death (whatever occurs first).
Title
Quality of Life measures with EORTC QLQ-C30 Global Health Status (GHS)
Description
GHS scale-core item 29, 30; ranges 0-100
Time Frame
Baseline, 6, and 12 months after randomization
Title
Quality of Life measures with EORTC QLQ-C30 Symptom Scale Insomnia
Description
Item 11, ranges 0-100
Time Frame
Baseline, 6, and 12 months after randomization
Title
Quality of Life measures with EORTC QLQ-C30 Symptom Scale Constipation
Description
Item 16, ranges 0-100
Time Frame
Baseline, 6, and 12 months after randomization
Title
Quality of Life measures with FACT-G total score
Description
Composite of 27 items regarding physical, functional, social/family and emotional well-being. from 0-108
Time Frame
Baseline, 6, and 12 months after randomization
Title
Quality of Life measures with FACT-O Ovarian Cancer subscale
Description
Composite of 11 items regarding specific to Ovarian Cancer patients, ranges 0-44
Time Frame
Baseline, 6, and 12 months after randomization
Title
Quality of Life measures with FACT-O total score
Description
Sum of FACT-G and and Ovarian Cancer subscale, ranges 0-152
Time Frame
Baseline, 6, and 12 months after randomization

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Patients with first recurrence of platinum sensitive, invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer of any initial stage. Progression-free interval of at least 6 months after end of last platinum-containing therapy, or recurrence within 6 months or later after primary surgery if the patient has not received prior chemotherapy in patients with FIGO I. Non cytostatic maintenance therapy not containing platinum will not be considered for this calculation. A positive AGO-score. Obligatory requirements for a positive AGO recurrence score in platinum-sensitive disease: Performance status ECOG 0 No residual tumor after primary surgery (if unknown, alternatively primary FIGO stage I/II). If report from 1st surgery is not available contact study chairman who will decide whether inclusion is possible or not. Absence of ascites (cut off < 500 ml: radiological or ultrasound estimation) Complete resection of the tumor by median laparotomy seems possible Patients who have given their signed and written informed consent and their consent to data transmission and -processing. Exclusion Criteria: Patients with non-epithelial tumors as well as borderline tumors. Patients without recurrence who are scheduled for diagnostic/second-look surgery or debulking surgery after completion of chemotherapy More than one prior chemotherapy Patients with second, third, or later recurrence Patients with second malignancies who have been treated by laparotomy, as well as other neoplasms, if the treatment might interfere with the treatment of relapsed ovarian cancer or if major impact on prognosis is expected. Patients with so-called platinum-refractory tumor, i.e. progression during chemotherapy or recurrence within 6 months after end of former first platinum-containing therapy Only palliative surgery planned Radiological signs suggesting metastases not accessible to surgical removal (i.e. complete resection is deemed impossible) Any concomitant disease not allowing surgery and/or chemotherapy Any medical history indicating excessive peri-operative risk Any current medication inducing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents, bevacizumab)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philipp Harter, MD
Organizational Affiliation
AGO Study Group
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medizinische Universität Graz, Universitätsklinik für Frauenheilkunde Graz, Abteilung Gynäkologie u. Geburtshilfe
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Universitätsklinikum Innsbruck, Univ. Klinik für Gynäkologie und Geburtshilfe
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Medizinische Universität Wien,Universitätsklinik für Frauenheilkunde
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
Wilhelminenspital der Stadt Wien, Gynäkologisch und Geburtshilfliche Abteilung
City
Wien
ZIP/Postal Code
1160
Country
Austria
Facility Name
UZ Leuven
City
Leuven
Country
Belgium
Facility Name
Zhejiang Cancer Hospital, Gynecology Oncology
City
Hangzhou
ZIP/Postal Code
310022
Country
China
Facility Name
Fudan University Cancer Hospital, Gynecologic Oncology
City
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Name
Fudan University Zhongshan Hospital, Obstetrics and Gynecology
City
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Name
Suzhou Municipal Hospital, Gynecologic and Obstetrics
City
Suzhou
ZIP/Postal Code
215002
Country
China
Facility Name
Aalborg Hospital
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Facility Name
Aarhus University Hospital,Oncology
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark
Facility Name
Ringshospitalet Copenhagen University Hospital; Oncology
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Facility Name
Herlev Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Facility Name
Odense University Hospital, Gynaecology and Obstetrics
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Facility Name
Institut Bergonié, Gynecology
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Facility Name
Centre Francois Baclesse
City
Caen
ZIP/Postal Code
14000
Country
France
Facility Name
Centre Jean Perrin
City
Clermont-Ferrand
ZIP/Postal Code
63000
Country
France
Facility Name
Centre Antoine Lacassagne
City
Nice
ZIP/Postal Code
Cedex 02 06189
Country
France
Facility Name
Hôpital Européen Georges Pompidou
City
Paris
ZIP/Postal Code
Cedex 15 75015
Country
France
Facility Name
Hôpital Tenon
City
Paris
ZIP/Postal Code
Cedex 20 75020
Country
France
Facility Name
Insitut Jean Godinot, Service Rubis - Oncologie Médicale
City
Reims
ZIP/Postal Code
51056
Country
France
Facility Name
Centre Eugène Marquis
City
Rennes
ZIP/Postal Code
35042
Country
France
Facility Name
Centre Hospitalier Universitaire Charles-Nicolle
City
Rouen
ZIP/Postal Code
76000
Country
France
Facility Name
Centre Henri Becquerel
City
Rouen
ZIP/Postal Code
76038
Country
France
Facility Name
Centre René Gauducheau
City
Saint-Herblain
ZIP/Postal Code
44805
Country
France
Facility Name
Centre Claudius Regaud
City
Toulouse
ZIP/Postal Code
31052
Country
France
Facility Name
Hochtaunus-Kliniken gGmbH, Frauenklinik
City
Bad Homburg
ZIP/Postal Code
61348
Country
Germany
Facility Name
Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Facility Name
Universitätsklinikum Carl Gustav Carus, Klinik für Frauenheilkunde u. Geburtshilfe
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Evangelisches Krankenhaus, Frauenklinik
City
Düsseldorf
ZIP/Postal Code
40217
Country
Germany
Facility Name
Kaiserswerther-Diakonie, Florence-Nightingale Krankenhaus, Gynäkologie
City
Düsseldorf
ZIP/Postal Code
40489
Country
Germany
Facility Name
Kliniken Essen Mitte, Evang. Huyssens-Stiftung, Gynäkologische Onkologie
City
Essen
ZIP/Postal Code
45136
Country
Germany
Facility Name
Klinikum der JWG Universität Frankfurt, Klinik für Gynäkologie und Geburtshilfe
City
Frankfurt am Main
ZIP/Postal Code
60591
Country
Germany
Facility Name
Universitätsklinikum Freiburg, Frauenklinik
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Klinikum Fürth, Frauenklinik Nathanstift
City
Fürth
ZIP/Postal Code
90766
Country
Germany
Facility Name
Gynecologic Clinic of the Ernst-Moritz-Arndt-University
City
Greifswald
ZIP/Postal Code
17487
Country
Germany
Facility Name
Georg-August-Universität Göttingen, Universitäts-Frauenklinik
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Medizinische Hochschule, Klinik für Frauenheilkunde u. Geburtshilfe
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Klinikum Kempten, Klinik für Frauenheilkunde und Geburtshilfe
City
Kempten
ZIP/Postal Code
87439
Country
Germany
Facility Name
Universitätsklinikum Schleswig-Holstein Campus Kiel, Klinik f. Gynäkologie u. Geburtshilfe
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
Klinikum Konstanz, Frauenklinik
City
Konstanz
ZIP/Postal Code
78464
Country
Germany
Facility Name
Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Universitätsklinikum Mainz, Frauenklinik
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Klinikum Dritter Orden, Gynäkologie und Geburtshilfe
City
München
ZIP/Postal Code
80658
Country
Germany
Facility Name
Klinikum der Universität München-Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
City
München
ZIP/Postal Code
81377
Country
Germany
Facility Name
Oberschwaben Klinik, Krankenhaus St. Elisabeth, Frauenklinik
City
Ravensburg
ZIP/Postal Code
88212
Country
Germany
Facility Name
Caritas-Krankenhaus St. Josef, Klinik für Frauenheilkunde und Geburtshilfe d. Universität Regensburg
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Facility Name
Leopoldina-Krankenhaus der Stadt Schweinfurt GmbH, Frauenklinik
City
Schweinfurt
ZIP/Postal Code
97422
Country
Germany
Facility Name
Universitätsklinikum, Universitätsfrauenklinik
City
Ulm
ZIP/Postal Code
89075
Country
Germany
Facility Name
Ammerland-Klinik GmbH, Frauenklinik
City
Westerstede
ZIP/Postal Code
26655
Country
Germany
Facility Name
HSK, Dr. Horst Schmidt Klinik GmbH, Klinik für Gynäkologie u. Gynäkologische Onkologie
City
Wiesbaden
ZIP/Postal Code
65199
Country
Germany
Facility Name
Centro di Riferimento Oncologico,Struttura Operativa complessa Chirurgia Oncologica Ginecologica
City
Aviano
ZIP/Postal Code
33081
Country
Italy
Facility Name
Fondazione IRCCS Istituto Nazionale Tumori di Milano
City
Milan
ZIP/Postal Code
20133
Country
Italy
Facility Name
Istituto Europeo di Oncologia, Divisione di Ginecologia
City
Milan
ZIP/Postal Code
20141
Country
Italy
Facility Name
Istituto Nazionale Tumori di Napoli, Gynecologic Oncology
City
Naples
ZIP/Postal Code
80100
Country
Italy
Facility Name
Seoul National University Hospital, Department of Obstetrics and Gynecology
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
Facility Name
Norwegian Radium Hospital, Oslo University Hospital, Gynecologic Oncology
City
Oslo
ZIP/Postal Code
0310
Country
Norway
Facility Name
ICO Badalona - H. U. Germans Trias i Pujol
City
Badalona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Hospital de la Santa Creu i Sant Pau, Oncology
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Facility Name
Hospital Clinic Barcelona, Oncology
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
ICO-Hospital Universitari de Girona Dr. Josep Trueta, Servicio de Oncologia de Girona
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
Avinguda Granvia de l'Hospitalet de Llobregat, Hospital de Bellvitge, Gynaecology
City
Hospitalet de Llobregat
ZIP/Postal Code
08907
Country
Spain
Facility Name
Hospital Son Llàtzer, Oncology
City
Palma de Mallorca
ZIP/Postal Code
07198
Country
Spain
Facility Name
Hospital de Navarra, Oncology
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
Fundación Instituto Valenciano de Oncologia
City
Valencia
ZIP/Postal Code
46009
Country
Spain
Facility Name
Hospital Universitari i Politècnic la Fe, Oncology
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Linköping University Hospital, Department of Obstetrics and Gynecology
City
Linköping
ZIP/Postal Code
58185
Country
Sweden
Facility Name
Karolinska University Hospital, Oncology
City
Stockholm
ZIP/Postal Code
17176
Country
Sweden
Facility Name
Birmingham City Hospital, Cancer Research Team
City
Birmingham
ZIP/Postal Code
B18 7QH
Country
United Kingdom
Facility Name
Cambridge University Hospitals NHS FT - Addenbrookes Hospital, Gynaecological Oncology
City
Cambridge
ZIP/Postal Code
CB2 2QQ
Country
United Kingdom
Facility Name
Queen Elizabeth Hospital Gateshead, Northern gynaecological oncology centre
City
Gateshead
ZIP/Postal Code
NE9 6SX
Country
United Kingdom
Facility Name
Royal Surrey Country Hospital,St Lukes Cancer Centre
City
Guildford
ZIP/Postal Code
GU2 7XX
Country
United Kingdom
Facility Name
Lincoln County Hospital, Oncology
City
Lincoln
ZIP/Postal Code
LN2 5QY
Country
United Kingdom
Facility Name
St Bartholomew´s Hospital and Queen´s Hospital,Gynaecological Cancer Centre
City
London
ZIP/Postal Code
C14 7BE
Country
United Kingdom
Facility Name
University College London Hospital, Cancer clinical trails unit
City
London
ZIP/Postal Code
NW1 2 PG
Country
United Kingdom
Facility Name
Royal Marsden NHS Foundation Trust, Gynae research, Mulberry House
City
London
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Facility Name
Imperial College Healthcare NHS Trust Hammersmith Hospital, Medical Oncology
City
London
ZIP/Postal Code
W12 0HS
Country
United Kingdom
Facility Name
Central Manchester Foundation NHS Trust, St Mary´s Hospital, Gynaecology
City
Manchester
ZIP/Postal Code
M13 9W
Country
United Kingdom
Facility Name
Queen Elizabeth the Queen Mother Hospital,East Kent Gynaeoncology Centre
City
Margate
ZIP/Postal Code
CT9 4AN
Country
United Kingdom
Facility Name
Northampton General Hospital, Gynaecological Oncology
City
Northampton
ZIP/Postal Code
NN1 5 BD
Country
United Kingdom
Facility Name
East and North Hertfordhire NHS Trust,Mount Vernon Hospital,Medical Oncology
City
Northwood
ZIP/Postal Code
HA6 2RN
Country
United Kingdom
Facility Name
Norfolk & Norwich University Hospital,Obstetrics & Gynaecology
City
Norwich
ZIP/Postal Code
NR4 7UY
Country
United Kingdom
Facility Name
Nottingham University Hospital, City Campus, Oncology
City
Nottingham
ZIP/Postal Code
NG7 2UH
Country
United Kingdom
Facility Name
Royal Hallamshire Hospital & Weston Park Hospital, Cancer Clinical Trials Centre
City
Sheffield
ZIP/Postal Code
S10 2SJ
Country
United Kingdom
Facility Name
Princess Anne Hospital, gynaecology
City
Southampton
ZIP/Postal Code
SO16 5YA
Country
United Kingdom
Facility Name
New Cross Hospital,Oncology/Gynaecology
City
Wolverhampton
ZIP/Postal Code
WV10 OQP
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
34874631
Citation
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, Pomel C, Lecuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A; DESKTOP III Investigators. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294. Erratum In: N Engl J Med. 2022 Feb 17;386(7):704.
Results Reference
result
PubMed Identifier
29743148
Citation
Bommert M, Harter P, Heitz F, du Bois A. When should Surgery be used for Recurrent Ovarian Carcinoma? Clin Oncol (R Coll Radiol). 2018 Aug;30(8):493-497. doi: 10.1016/j.clon.2018.04.006. Epub 2018 May 7.
Results Reference
derived

Learn more about this trial

Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer

We'll reach out to this number within 24 hrs